BioPorto.jpg
BioPorto adds Mr. Nis Kruse as EVP of Strategic Partnerships and GM of EMEA & APAC
05 déc. 2022 12h52 HE | BioPorto A/S
COPENHAGEN, Denmark and BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) today announced that Mr. Nis Kruse joined the Company as EVP of Strategic...
BioPorto.jpg
BioPorto Announces Interim Results for the First Nine Months of 2022
09 nov. 2022 02h05 HE | BioPorto A/S
Announcement no. 15 COPENHAGEN, Denmark and BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first nine months of...
BioPorto Logo with name.jpg
BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call
03 nov. 2022 12h05 HE | BioPorto A/S
COPENHAGEN, Denmark and BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of kidney injury,...
BioPorto Logo with name.jpg
BioPorto to Participate in H.C. Wainwright’s 24th Annual Global Investment Conference
08 sept. 2022 08h00 HE | BioPorto A/S
COPENHAGEN, Denmark and BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced plans to participate in the H.C. Wainwright 24th Annual Global Investment...
BioPorto Logo with name.jpg
BioPorto Announces Interim Results for the First Six Months of 2022
17 août 2022 02h20 HE | BioPorto A/S
COPENHAGEN, Denmark and BOSTON, Aug. 17, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first six months of 2022 and business...
BioPorto Logo with name.jpg
BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call
08 août 2022 11h05 HE | BioPorto A/S
COPENHAGEN, Denmark and BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of kidney injury,...
BioPorto Logo with name.jpg
BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.
28 juin 2022 15h02 HE | BioPorto A/S
COPENHAGEN, Denmark and BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced its achievement of targeted subject enrollment for the third part of a 3-part...
BioPorto Logo with name.jpg
Moderated Webcast with BioPorto’s Management
21 juin 2022 11h00 HE | BioPorto A/S
COPENHAGEN, Denmark and BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (CPH:BIOPOR) (BioPorto) today provided details of a previously announced session with members of its management team. ...
BioPorto Logo with name.jpg
BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr. Prasad Devarajan, MD FAAP FASN, as New Senior Medical Director
20 juin 2022 02h15 HE | BioPorto A/S
COPENHAGEN, Denmark and BOSTON, June 20, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (CPH:BIOPOR) (BioPorto) today announced the appointment of Dr. Prasad Devarajan, MD FAAP FASN, as Senior Medical...
Logo.jpg
BioPorto Appoints New President of BioPorto Diagnostics, Inc.
15 avr. 2019 09h00 HE | BioPorto A/S
Company Plans to Bring Novel Kidney Diagnostic to US Market Hellerup, Denmark, April 15, 2019 (GLOBE NEWSWIRE) -- Today, BioPorto A/S CPH: BIOPOR (“BioPorto”) announces the appointment of Amy...